17.05.2024 17:15:06 - dpa-AFX: GNW-Adhoc: BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) - BioNTech SE
(https://www.biontech.com/int/en/home.html) (Nasdaq: BNTX, "BioNTech" or the
"Company") held its Annual General Meeting ("AGM") today, May 17, 2024. A total
of 87.51 per cent of the share capital was represented at the virtual assembly.
There were 14 items on the agenda of the AGM. All resolutions proposed on the
agenda items put to the vote at today's AGM were approved by a large majority of
the shareholders.
"The past few years marked a leap in competence for BioNTech," said Helmut
Jeggle, Chairman of the Supervisory Board of BioNTech. "With the development and
commercialization of a leading COVID-19 vaccine, BioNTech has shown that it can
deliver against targeted objectives successfully. Today, BioNTech's robust
financial position is an excellent foundation for its transformation into a
multi-product company, with particular focus on achieving commercial readiness
in oncology."
"2023 was a year in which we made important progress in many areas: We
maintained a leading position in the COVID-19 vaccine market, published
encouraging data for candidates in our oncology pipeline and launched
potentially registrational trials. Additionally, we have strengthened our
organization in preparation for the next phase of growth, particularly with
regards to our planned product launches in oncology," said Prof. Ugur Sahin,
M.D., CEO and Co-Founder of BioNTech. "We believe that our therapies under
development, once approved, have the potential to complement or replace
established cancer treatment approaches in many areas in the future."
The voting results for all agenda items can be seen on the Annual General
Meeting 2024 (https://investors.biontech.de/agm/agm-2024) website under the
section 'Voting Results'. The speech by Prof. Ugur Sahin, M.D., and the slides
presented at the AGM 2024 can be found in section 'Speeches and Presentations'
under the same link.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation
immunotherapy company pioneering novel therapies for cancer and other serious
diseases. BioNTech exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product candidates includes
individualized and off-the-shelf mRNA-based therapies, innovative chimeric
antigen receptor (CAR) T cells, several protein-based therapeutics, including
bispecific immune checkpoint modulators, targeted cancer antibodies and
antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on
its deep expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing multiple mRNA
vaccine candidates for a range of infectious diseases alongside its diverse
oncology pipeline. BioNTech has established a broad set of relationships with
multiple global and specialized pharmaceutical collaborators, including
Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group,
Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com (http://www.BioNTech.com).
Forward-Looking Statements
This press release contains "forward-looking statements" of BioNTech within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-
looking statements may include, but may not be limited to, statements concerning
BioNTech's financial position; BioNTech's research and development programs,
including statements characterizing timing, related preparatory work, and the
availability of results; and BioNTech's preparations for potential product
launches in oncology. Any forward-looking statements in this press release are
based on BioNTech's current expectations and beliefs of future events. The
forward-looking statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these forward-looking
statements because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond BioNTech's control, and which could
cause actual results to differ materially from those expressed or implied by
these forward-looking statements.
You should review the risks and uncertainties described under the heading "Risk
Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2024
and in subsequent filings made by BioNTech with the SEC, which are available on
the SEC's website at www.sec.gov (http://www.sec.gov). These forward-looking
statements speak only as of the date hereof. Except as required by law, BioNTech
disclaims any intention or responsibility for updating or revising any forward-
looking statements contained in this press release in the event of new
information, future developments or otherwise.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de (mailto:Investors@biontech.de)
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de (mailto:Media@biontech.de)
Â